发布求助
文献互助 智能选刊 最新文献

Leukemia & Lymphoma最新文献

筛选
英文 中文
Are we maintaining minimal residual disease in myeloma? 我们是否在骨髓瘤中维持最小残留病变？
IF 2.2 4区 医学
Leukemia & Lymphoma Pub Date : 2025-01-21 DOI: 10.1080/10428194.2025.2455485
Mohammed A Aljama, Hasib M Sidiqi, Morie A Gertz
{"title":"Are we maintaining minimal residual disease in myeloma?","authors":"Mohammed A Aljama, Hasib M Sidiqi, Morie A Gertz","doi":"10.1080/10428194.2025.2455485","DOIUrl":"https://doi.org/10.1080/10428194.2025.2455485","url":null,"abstract":"<p><p>Minimal residual disease (MRD) has emerged as an important prognostic maker in patients with multiple myeloma at different stages of their treatment. Moreover, it is being increasingly incorporated as an endpoint in various clinical trials. Since maintenance therapy is an integral part of myeloma treatment, especially in the upfront setting post autologous transplantation, it is imperative to understand the role of MRD testing in the maintenance stetting. This review aims to examine the utility and dynamics of MRD testing in order to elucidate its prognostic role and possible incorporation in clinical decision making processes.</p>","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1-9"},"PeriodicalIF":2.2,"publicationDate":"2025-01-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143007894","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Phase 2 trial of ibrutinib in previously untreated high-risk smoldering mantle cell lymphoma. 依鲁替尼治疗先前未治疗的高风险阴燃套细胞淋巴瘤的2期试验。
IF 2.2 4区 医学
Leukemia & Lymphoma Pub Date : 2025-01-21 DOI: 10.1080/10428194.2025.2454540
Charles Gaulin, Preetesh Jain, Ranjit Nair, Swaminathan P Iyer, Hun Ju Lee, Luis Fayad, Lei Feng, Chi Young Ok, Rashmi Kanagal-Shamanna, Onyeka Oriabure, Wendy Chen, Guofan Xu, Anita Deswal, Cezar Iliescu, Maria Badillo, Michelle Ky, Michelle Avellaneda, Guilin Tangc, L Jeffrey Medeiros, Francisco Vega, Christopher R Flowers, Michael L Wang
{"title":"Phase 2 trial of ibrutinib in previously untreated high-risk smoldering mantle cell lymphoma.","authors":"Charles Gaulin, Preetesh Jain, Ranjit Nair, Swaminathan P Iyer, Hun Ju Lee, Luis Fayad, Lei Feng, Chi Young Ok, Rashmi Kanagal-Shamanna, Onyeka Oriabure, Wendy Chen, Guofan Xu, Anita Deswal, Cezar Iliescu, Maria Badillo, Michelle Ky, Michelle Avellaneda, Guilin Tangc, L Jeffrey Medeiros, Francisco Vega, Christopher R Flowers, Michael L Wang","doi":"10.1080/10428194.2025.2454540","DOIUrl":"https://doi.org/10.1080/10428194.2025.2454540","url":null,"abstract":"","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1-5"},"PeriodicalIF":2.2,"publicationDate":"2025-01-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143007620","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Unmet needs and lived experience of patients receiving CAR T-cell therapy. 接受CAR - t细胞治疗的患者未满足的需求和生活经历。
IF 2.2 4区 医学
Leukemia & Lymphoma Pub Date : 2025-01-21 DOI: 10.1080/10428194.2025.2455488
Patrick J O'Shea, Patrick Connor Johnson, Areej El-Jawahri, Thomas W Leblanc
{"title":"Unmet needs and lived experience of patients receiving CAR T-cell therapy.","authors":"Patrick J O'Shea, Patrick Connor Johnson, Areej El-Jawahri, Thomas W Leblanc","doi":"10.1080/10428194.2025.2455488","DOIUrl":"https://doi.org/10.1080/10428194.2025.2455488","url":null,"abstract":"<p><p>Chimeric Antigen Receptor T-Cell (CAR-T) therapy is an effective therapy and promising frontier in the treatment of hematologic malignancies. However, this revolutionary treatment has led to new challenges for patients, caregivers, and the healthcare system. In this review article, we discuss the various difficulties patients face both in the acute and long-term period following CAR-T infusion. We highlight the various ways these difficulties are addressed, as well as further areas of research and support needed to improve patient experience. Additionally, we consider the difficulties and burdens placed on caregivers and healthcare systems, as well as barriers to accessing CAR-T therapy. Finally, we address future directions of research and intervention development to meet patient and caregiver needs and improve equitable access. We pose early integration of specialty palliative care for individuals and their caregivers undergoing CAR-T therapy as one promising strategy to help improve patient experience and meet their needs.</p>","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1-11"},"PeriodicalIF":2.2,"publicationDate":"2025-01-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143007806","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The challenge of targeting key drivers of CLL and sequencing therapy in an era of experimental therapeutics. 在实验疗法时代，针对CLL关键驱动因素和测序治疗的挑战。
IF 2.2 4区 医学
Leukemia & Lymphoma Pub Date : 2025-01-19 DOI: 10.1080/10428194.2024.2445688
Britten K Gordon, Jennifer A Woyach
{"title":"The challenge of targeting key drivers of CLL and sequencing therapy in an era of experimental therapeutics.","authors":"Britten K Gordon, Jennifer A Woyach","doi":"10.1080/10428194.2024.2445688","DOIUrl":"https://doi.org/10.1080/10428194.2024.2445688","url":null,"abstract":"<p><p>Treatment of chronic lymphocytic leukemia (CLL) has been revolutionized with the introduction of small molecule inhibitors targeting both the B-cell receptor (BCR) signaling pathway and B-cell lymphoma-2 (BCL-2) family of proteins. Inhibitors of Bruton's tyrosine kinase (BTK) and the BH3 mimetic venetoclax are bothcurrently used as the standard of care for patients in the frontline and relapsed/refractory setting of CLL. With the clinical success of both these classes of therapies, sequencing of these agents has become a major challenge in treatment of CLL. In this review we will discuss the current data available for both classes of agents in the front-line and relapsed/refractor setting, considerations when giving these agents, and how we can continue to improve the treatment landscape for CLL.</p>","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1-9"},"PeriodicalIF":2.2,"publicationDate":"2025-01-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143007674","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Bruton's tyrosine kinase inhibitor zanubrutinib-based regimens in relapsed/refractory primary diffuse large B-cell lymphoma of the central nervous system. 基于Bruton酪氨酸激酶抑制剂zanubrutinib的方案治疗复发/难治性中枢神经系统原发性弥漫性大b细胞淋巴瘤
IF 2.2 4区 医学
Leukemia & Lymphoma Pub Date : 2025-01-17 DOI: 10.1080/10428194.2025.2451066
Yali Wang, Jiefei Han, Shuo Yin, Shoubo Yang, Xun Kang, Xiaohong Zheng, Ling Duan, Shenglan Li, Bo Jiang, Wenbin Li, Feng Chen
{"title":"Bruton's tyrosine kinase inhibitor zanubrutinib-based regimens in relapsed/refractory primary diffuse large B-cell lymphoma of the central nervous system.","authors":"Yali Wang, Jiefei Han, Shuo Yin, Shoubo Yang, Xun Kang, Xiaohong Zheng, Ling Duan, Shenglan Li, Bo Jiang, Wenbin Li, Feng Chen","doi":"10.1080/10428194.2025.2451066","DOIUrl":"10.1080/10428194.2025.2451066","url":null,"abstract":"<p><p>Patients with relapsed/refractory primary central nervous system lymphoma (R/R PCNSL) usually have a poor prognosis and limited treatment options. We respectively reviewed 38 patients with R/R PCNSL treated with zanubrutinib-based regimens in our center. The overall response rate, complete response rate and disease control rate were 76.3%, 47.4% and 92.1%, respectively. The median progression-free survival (PFS) was 31.0 months, the median overall survival (OS) was not reached. Unitivariate analysis by Cox's proportional hazards model revealed that overall response (vs. no response, HR = 0.18, 95%CI:0.07,0.48, <i>p</i> = 0.001), long duration of zanubrutinib (≥6months vs 2-5 months, HR = 0.20, 95%CI:0.06,0.63, <i>p</i> = 0.006) were independent factors for prolonged PFS. The log-rank analysis indicated a prolongation of PFS among patients exhibiting a higher Tumor mutational burden (TMB, ≥14.75muts/Mb) following zanubrutinib-based treatment (<i>p</i> = 0.016). Our data showed promising efficacy with tolerable safety of zanubrutinib-based therapies in patients with R/R PCNSL. Long duration of zanubrutinib may be associated with prolonged PFS.</p>","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1-10"},"PeriodicalIF":2.2,"publicationDate":"2025-01-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143007898","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comprehensive analysis of clinical, pathological, and molecular features in chronic myelomonocytic leukemia: frequent ASXL1 and NRAS mutations and higher mutation burden in myeloproliferative CMML compared to myelodysplastic CMML. 慢性髓单细胞白血病临床、病理和分子特征的综合分析：与骨髓增生异常CMML相比，骨髓增生性CMML中ASXL1和NRAS突变频繁，突变负担更高。
IF 2.2 4区 医学
Leukemia & Lymphoma Pub Date : 2025-01-17 DOI: 10.1080/10428194.2025.2453093
Yoonseo Jeong
{"title":"Comprehensive analysis of clinical, pathological, and molecular features in chronic myelomonocytic leukemia: frequent <i>ASXL1</i> and <i>NRAS</i> mutations and higher mutation burden in myeloproliferative CMML compared to myelodysplastic CMML.","authors":"Yoonseo Jeong","doi":"10.1080/10428194.2025.2453093","DOIUrl":"https://doi.org/10.1080/10428194.2025.2453093","url":null,"abstract":"<p><p>Various aspects of myeloproliferative chronic myelomonocytic leukemia (MP-CMML) and myelodysplastic CMML (MD-CMML) have been reported but inconsistencies remain. This study conducted a comprehensive retrospective analysis of clinical, pathological, and molecular data from a cohort of CMML. The results revealed a higher frequency of <i>ASXL1</i> and <i>NRAS</i> mutations and a greater mutation burden in MP-CMML, characterized by more tier 1 or 2 variants and dominant mutations. Significant genotype-phenotype correlations were observed, including distinct patterns within MD-CMML subgroups. Additionally, <i>NRAS</i> or <i>RUNX1</i> mutations and an abnormal karyotype were associated with worse overall survival or progression-free survival. These findings underscore the distinct molecular and pathological differences between MP-CMML and MD-CMML, highlighting the more aggressive nature of MP-CMML and the need for tailored treatment strategies.</p>","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1-10"},"PeriodicalIF":2.2,"publicationDate":"2025-01-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143007900","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Venetoclax in combination with fludarabine, cytarabine, granulocyte colony stimulating factor, and idarubicin (FLAG-Ida) in patients with acute leukemia of ambiguous lineage and acute lymphoblastic leukemia. Venetoclax联合氟达拉滨、阿糖胞苷、粒细胞集落刺激因子和依达柔比星（FLAG-Ida）治疗血统不明的急性白血病和急性淋巴细胞白血病。
IF 2.2 4区 医学
Leukemia & Lymphoma Pub Date : 2025-01-16 DOI: 10.1080/10428194.2024.2443017
Steven Tessier, Kristen B McCullough, Naseema Gangat, Kebede H Begna, Antoine N Saliba, Abhishek A Mangoankar, Mithun V Shah, William J Hogan, Mrinal M Patnaik, Aref Al-Kali, Hassan B Alkhateeb
{"title":"Venetoclax in combination with fludarabine, cytarabine, granulocyte colony stimulating factor, and idarubicin (FLAG-Ida) in patients with acute leukemia of ambiguous lineage and acute lymphoblastic leukemia.","authors":"Steven Tessier, Kristen B McCullough, Naseema Gangat, Kebede H Begna, Antoine N Saliba, Abhishek A Mangoankar, Mithun V Shah, William J Hogan, Mrinal M Patnaik, Aref Al-Kali, Hassan B Alkhateeb","doi":"10.1080/10428194.2024.2443017","DOIUrl":"https://doi.org/10.1080/10428194.2024.2443017","url":null,"abstract":"","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1-5"},"PeriodicalIF":2.2,"publicationDate":"2025-01-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143007809","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Assessment of frailty and comorbidities in cellular therapies patients in Italy: results of the GITMO Elderly-Survey (GITMO ELD-Survey). 评估意大利细胞治疗患者的衰弱和合并症：GITMO老年调查（GITMO老年调查）的结果。
IF 2.2 4区 医学
Leukemia & Lymphoma Pub Date : 2025-01-15 DOI: 10.1080/10428194.2025.2451723
Michele Malagola, Luca Castagna, Mirko Farina, Simone Pellizzeri, Eliana Degrandi, Elena Oldani, Simona Bassi, Giorgia Battipaglia, Carlo Borghero, Lucia Brunello, Alessandro Busca, Raffaella Ceretti, Patrizia Chiusolo, Michele Cimminiello, Vincenzo Federico, Camilla Frieri, Piero Galieni, Sara Galimberti, Andrea Gilioli, Annalisa Imovilli, Walter Barbieri, Chiara Nozzoli, Alessandra Picardi, Eugenia Piras, Nicola Polverelli, Lucia Prezioso, Stella Santarone, Renato Scalone, Ilaria Scortechini, Bianca Serio, Cristina Skert, Alessandro Spina, Elisabetta Terruzzi, Massimo Martino
{"title":"Assessment of frailty and comorbidities in cellular therapies patients in Italy: results of the GITMO Elderly-Survey (GITMO ELD-Survey).","authors":"Michele Malagola, Luca Castagna, Mirko Farina, Simone Pellizzeri, Eliana Degrandi, Elena Oldani, Simona Bassi, Giorgia Battipaglia, Carlo Borghero, Lucia Brunello, Alessandro Busca, Raffaella Ceretti, Patrizia Chiusolo, Michele Cimminiello, Vincenzo Federico, Camilla Frieri, Piero Galieni, Sara Galimberti, Andrea Gilioli, Annalisa Imovilli, Walter Barbieri, Chiara Nozzoli, Alessandra Picardi, Eugenia Piras, Nicola Polverelli, Lucia Prezioso, Stella Santarone, Renato Scalone, Ilaria Scortechini, Bianca Serio, Cristina Skert, Alessandro Spina, Elisabetta Terruzzi, Massimo Martino","doi":"10.1080/10428194.2025.2451723","DOIUrl":"https://doi.org/10.1080/10428194.2025.2451723","url":null,"abstract":"","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1-4"},"PeriodicalIF":2.2,"publicationDate":"2025-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143007896","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
High incidence of multi-joint osteonecrosis in first year following treatment for acute lymphoblastic leukemia. 急性淋巴细胞白血病治疗后第一年多关节骨坏死的高发。
IF 2.2 4区 医学
Leukemia & Lymphoma Pub Date : 2025-01-15 DOI: 10.1080/10428194.2025.2452340
Alison K Heilbronner, Olivia Blumberg, Alexandra Krez, Donald J McMahon, Douglas N Mintz, Joseph M Lane, Richard S Bockman, Kyung-Hyun Park-Min, Derek Hansen, Shreya Addepalli, Gail J Roboz, Emily M Stein
{"title":"High incidence of multi-joint osteonecrosis in first year following treatment for acute lymphoblastic leukemia.","authors":"Alison K Heilbronner, Olivia Blumberg, Alexandra Krez, Donald J McMahon, Douglas N Mintz, Joseph M Lane, Richard S Bockman, Kyung-Hyun Park-Min, Derek Hansen, Shreya Addepalli, Gail J Roboz, Emily M Stein","doi":"10.1080/10428194.2025.2452340","DOIUrl":"https://doi.org/10.1080/10428194.2025.2452340","url":null,"abstract":"","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1-4"},"PeriodicalIF":2.2,"publicationDate":"2025-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143007498","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Identification of possible drug treatment targets and related immune cell infiltration properties in acute myeloid leukemia utilizing robust rank aggregation algorithm. 利用鲁棒秩聚集算法识别急性髓系白血病可能的药物治疗靶点和相关免疫细胞浸润特性
IF 2.2 4区 医学
Leukemia & Lymphoma Pub Date : 2025-01-15 DOI: 10.1080/10428194.2025.2451064
Hengzhou Zhu, Chencen Zhang, Lei Huang, Baonan Zhang, Xiaona Huang, Jianliang You, Chunhui Jin
{"title":"Identification of possible drug treatment targets and related immune cell infiltration properties in acute myeloid leukemia utilizing robust rank aggregation algorithm.","authors":"Hengzhou Zhu, Chencen Zhang, Lei Huang, Baonan Zhang, Xiaona Huang, Jianliang You, Chunhui Jin","doi":"10.1080/10428194.2025.2451064","DOIUrl":"https://doi.org/10.1080/10428194.2025.2451064","url":null,"abstract":"<p><p>In this study, we aimed to uncover novel biomarkers in acute myeloid leukemia (AML) that could serve as prognostic indicators or therapeutic targets. We analyzed AML microarray datasets from the Gene Expression Omnibus (GEO) repository, identifying key differentially expressed genes (DEGs) through the robust rank aggregation (RRA) approach. The functions of these DEGs were elucidated through Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses. Additionally, the CIBERSORT algorithm was employed to assess immune cell infiltration in AML. Six hub genes were identified using the cytoHubba plugin, and their clinical significance, survival impact, and meta-analyses were conducted. Through comprehensive bioinformatics and qPCR analyses, we gained new insights into AML pathogenesis and metastasis, identifying FCGR3B, FLT3, EREG, and MMP9 as potential prognostic biomarkers. Antagonists targeting FCGR3B, FLT3, and MMP9, or agonists for EREG, hold promise as therapeutic and preventative strategies for AML.</p>","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1-12"},"PeriodicalIF":2.2,"publicationDate":"2025-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143007615","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信